Aptorum Group Limited - Class A Ordinary Shares (APM)
1.2900
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 7th, 10:38 PM EDT
Detailed Quote
Previous Close
1.290
Open
1.310
Bid
1.280
Ask
1.300
Day's Range
1.270 - 1.330
52 Week Range
0.4600 - 4.800
Volume
64,117
Market Cap
4.97M
PE Ratio (TTM)
-1.654
EPS (TTM)
-0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
8,916,169
Chart
About Aptorum Group Limited - Class A Ordinary Shares (APM)
Aptorum Group Ltd is a biotechnology and pharmaceutical company focused on developing innovative therapeutic solutions to address significant unmet medical needs. The company is involved in the discovery and commercialization of new drugs, particularly in the areas of metabolic diseases, infectious diseases, and other major health challenges. Aptorum Group is dedicated to advancing its proprietary drug candidates through various stages of development, including preclinical and clinical trials, while also exploring strategic partnerships and collaborations to enhance its research capabilities and market reach. Read More
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq’s minimum bid price requirement.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.
Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering price of $2.00 per share.
Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024.
